Dow Jones 30 Stocks SEC Filings — April 30, 2026

30-04-2026

Altos Ventures Management, Inc. filed a 13F-HR report on April 30, 2026, for the quarter ended March 31, 2026, disclosing that it holds no Section 13(f) securities. The report confirms zero holdings across all categories.

• ·Business address: 250 California Dr, Floor 4, Burlingame, CA 94010
• ·Phone: (650) 234-9771
• ·SEC file number: 028-22167
• ·CIK: 0001881755

30-04-2026

Sentage Holdings Inc. (SNTG) filed its 20-F Annual Report on April 30, 2026. The excerpt discusses U.S. federal income tax considerations for holders of its Ordinary Shares, defining U.S. persons (including certain corporations, trusts, and substantial shareholders) and outlining Passive Foreign Investment Company (PFIC) status criteria based on passive income (75% threshold) or assets (50% threshold). It details taxation of excess distributions or gains, allocated ratably over the holding period and treated as ordinary income for prior non-PFIC years.

30-04-2026

Bob's Discount Furniture, Inc. (through BDF Acquisition Corp.) entered into Joinder Agreement and Amendment No. 10 to its Revolving Credit Agreement dated April 29, 2026, increasing Revolving Credit Commitments by $75 million from new Incremental Revolving Loan Lenders. Post-amendment, total Revolving Credit Commitments reach $200 million. The amendment includes updates to schedules, exhibits, and consents to pro rata adjustments in existing loans and letter of credit participations, with no Events of Default noted.

• ·Original Revolving Credit Agreement dated February 12, 2014, with prior amendments on June 17, 2016; June 18, 2018; September 18, 2019; May 12, 2021; July 5, 2022; August 24, 2022; June 2, 2024; July 1, 2024; and October 31, 2025.
• ·Effectiveness conditions include receipt of executed agreements, corporate resolutions, true representations/warranties, no Event of Default, legal opinion from Ropes & Gray LLP, and KYC documentation.
• ·Existing Lenders waive notice requirement under Section 2.14(a) and consent to the incremental commitments without using Maximum Incremental Facilities Amount.

30-04-2026

Nvni Group Ltd (operating as Nuvini S.A.) filed its 20-F Annual Report for the year ended December 31, 2025, detailing seven completed acquisitions including Munddi (100%) in May 2025 and a pending binding term sheet for MK Solutions signed September 30, 2025, alongside an active M&A pipeline of approximately 2,000 targets. Capital expenditures declined 44% YoY to R$9.0 million in 2025 from R$16.0 million in 2024, driven by lower capitalized development costs (R$6.0 million vs. R$14.2 million), though property and equipment spend fell to R$1.1 million from R$1.8 million. The report highlights portfolio diversification across B2B SaaS products serving 22,400 customers in 15 countries and potential synergies with Beyondsoft's IT services, where top five Fortune 100 customers represent 80% of revenue.

• ·Mercos acquisition: control assumed August 10, 2021 at 57.91% interest.
• ·MK Solutions acquisition pending, subject to customary conditions, due diligence, and closing; targets ERP for Brazilian internet providers.
• ·Beyondsoft top customers include Fortune 100/500 companies; potential Microsoft Master Services Agreement assignment noted as material, with risks in Item 3.D.

30-04-2026

Intellia Therapeutics entered into an underwriting agreement on April 28, 2026, for a public offering of 16,744,187 shares of common stock at $10.75 per share, with underwriters exercising the full 30-day option for an additional 2,511,628 shares, yielding net proceeds of approximately $194.6 million after discounts and expenses. As of March 31, 2026, the company's preliminary unaudited cash, cash equivalents, and marketable securities stood at $517.2 million, bolstered by $33.6 million in net proceeds from an at-the-market equity offering program during the quarter. The net proceeds will fund clinical development, pipeline advancement, potential acquisitions, and general corporate purposes, extending the cash runway into at least 2028.

• ·Offering closed on April 30, 2026; underwriter option exercised in full on April 29, 2026
• ·Potential approval of lonvoguran ziclumeran for hereditary angioedema anticipated in first half of 2027
• ·Underwriting agreement includes customary representations, warranties, covenants, and indemnification
• ·Preliminary financial data not audited or reviewed by Deloitte & Touche LLP

30-04-2026

Pioneer Bancorp reported first quarter 2026 net income of $5.3 million ($0.22 per share), down from $5.8 million ($0.23 per share) YoY, driven by noninterest expenses rising 24.2% to $18.1 million due to higher professional fees, salaries, and litigation costs. However, net interest income increased 8.7% YoY to $20.8 million with net interest margin expanding 9 basis points to 4.21%, supported by loan growth of 3.3% QoQ to $1.70 billion and deposits up 6.5% QoQ to $1.85 billion. The company completed acquisitions of Targeted Lending ($140 million enterprise value, $120 million loans), Reiser Consulting Group, and Wyndham Benefits to bolster specialty financing and employee benefits divisions.

• ·Non-performing assets declined to $9.0 million (0.40% of total assets) at March 31, 2026 from $11.3 million (0.52%) at December 31, 2025.
• ·Allowance for credit losses on loans was $26.0 million (1.51% of total loans) at March 31, 2026.
• ·Estimated uninsured deposits, net of affiliate and collateralized, were 14.4% of total deposits at March 31, 2026.
• ·Tier 1 (leverage) capital to average assets ratio of 11.56% at March 31, 2026, above well-capitalized standard.
• ·Effective tax rate decreased to 7.3% in Q1 2026 from 22.3% in Q1 2025 due to discrete tax item.

30-04-2026

MicroVision, Inc. filed an amended S-3/A shelf registration statement on April 30, 2026, to facilitate the resale by selling stockholders of up to 61,315,970 shares of common stock underlying approximately $43 million in senior secured convertible notes due 2028 issued to High Trail entities in February 2026. The filing highlights recent strategic acquisitions, including Scantinel Photonics assets in January 2026 and Luminar Technologies' lidar business in February 2026, expanding its solid-state lidar portfolio (MOVIA, MAVIN, IRIS, HALO, Scantinel FMCW). However, the company reports significant ongoing losses (FY2025 loss per share of $0.35), stock price volatility (52-week low $0.53, high $1.50), and potential dilution from note conversions.

• ·Convertible notes have zero coupon, initial conversion price of $0.8819 per share, and monthly partial redemptions starting April 1, 2026.
• ·Forced conversion possible if stock price exceeds $2.00 for 20 consecutive VWAP trading days.
• ·Notes secured by first priority lien, with covenants including minimum liquidity and cash burn limits.
• ·52-week stock price range ending April 20, 2026: low $0.53, high $1.50.

30-04-2026

Hydrofarm Holdings Group, Inc. (HYFM) filed a DEFA14A form on April 30, 2026, consisting of Definitive Additional Proxy Materials pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive financial data, voting matters, or other details are provided in the available content.

30-04-2026

First Northern Community Bancorp reported first quarter 2026 net income of $5.9 million ($0.36 per diluted share), up 60.9% YoY from $3.7 million ($0.22 per diluted share), fueled by net interest income growth of 7.91% to $17.2 million, non-interest income up 19.75% to $1.7 million, and non-interest expense down 4.81% to $11.0 million. Total assets reached $1.92 billion (up 2.6% YoY), net loans $1.06 billion (up 2.3% YoY, driven by commercial but offset by declines in CRE, agriculture, residential, and consumer), and deposits $1.69 billion (up 1.2% YoY); however, QoQ net income declined 1.2% to $5.9 million from $6.0 million, net interest income fell 3.0%, and cash equivalents dropped 4.1%. The company issued a 5% stock dividend, announced a repurchase of up to 6% of shares, and uplisted to Nasdaq Capital Market post-quarter.

• ·ROAA 1.24% (up YoY from 0.79%, flat QoQ from 1.23%)
• ·ROAE 11.21% (down QoQ from 11.40%, up YoY from 8.23%)
• ·Total risk-based capital ratio exceeds 10%, with Total capital ratio 19.1%
• ·Book value per share $13.03 (up from $12.92 at Dec 31 2025 and $11.25 at Mar 31 2025)
• ·Provision for credit losses $300k (vs $850k YoY and reversal of $850k QoQ)
• ·Cost of funds 0.90% (up slightly YoY from 0.86%)

30-04-2026

Hippo Holdings Inc. reported Q1 2026 net income of $7.1 million ($0.27 per diluted share) versus a $47.7 million net loss in Q1 2025, with adjusted net income of $17.2 million ($0.65 per diluted share) versus a $35.1 million adjusted net loss; gross written premium surged 58% YoY to $332.4 million, revenue grew 10% to $121.5 million, and combined ratio improved 60 points to 99.5%. However, net written premium grew only 1% to $101.4 million due to a drop in net retention to 31% from 48%, and the Renters line contracted $26 million YoY amid a one-time unearned premium adjustment. Updated FY2026 guidance raised gross written premium to $1.45-1.525 billion while maintaining combined ratio at 103-105%.

• ·Net earned premium increased 13% YoY to $98.9M.
• ·Expense ratio improved 2 pts to 51.5%.
• ·FY2026 guidance: Net Written Premium $520-550M (prior $500-540M), Adjusted Net Income $48-56M (prior $45-55M).
• ·Cash and cash equivalents $275.4M at Mar 31 2026 (up from $218.3M at year-end).
• ·Catastrophe losses $4.3M (4.3% of NEP) vs $53.4M (61.2%) prior year.

30-04-2026

Southside Bancshares reported Q1 2026 net income of $23.3 million, up 8.1% YoY from $21.5 million, with diluted EPS of $0.78 (up 9.9%) and linked quarter loan growth of 2.7% to $4.95 billion. Net interest income rose to $57.7 million (up 7.1% YoY and 0.8% linked), with tax-equivalent NIM expanding 3bps linked to 3.01%, while nonperforming assets fell sharply to 0.11% of total assets. However, noninterest expense increased 9.4% YoY and 8.3% linked quarter to $40.6 million, deposits grew only 0.1% linked quarter amid declines in retail (-1.6%) and public fund deposits (-1.7%), and efficiency ratio worsened to 56.44% from 53.85% linked quarter.

• ·Provision for credit losses on loans: $1.0 million in Q1 2026 (vs $0.6 million in Q4 2025)
• ·Q1 cash dividend: $0.36 per share, paid March 5, 2026
• ·No common stock repurchases under the Plan in Q1 2026; 0.8 million shares remain authorized
• ·Estimated uninsured deposits: 38.4% of total deposits (21.9% excluding affiliate and public fund deposits)
• ·Noninterest-bearing deposits: 20.0% of total deposits

30-04-2026

Lanvin Group Holdings Ltd filed its 20-F Annual Report on April 30, 2026, featuring forward-looking information disclaimers. The report highlights key risks such as potential impacts from health epidemics like COVID-19, challenges in safeguarding brand value and responding to customer preferences, inventory management issues leading to excess or shortages, IP protection failures, and reliance on dividends from subsidiaries which could limit cash flows if restricted. No financial metrics or performance data are detailed in the provided section.

30-04-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on April 30, 2026, announcing the issuance of a press release titled 'AITX's RAD Enters Hospitality Sector with First Major Hotel Brand Order.' This represents the company's expansion into the hospitality sector via its RAD product with its inaugural major order from a hotel brand. No financial details or performance metrics were disclosed.

30-04-2026

River Road Asset Management, LLC filed a 13F-HR reporting total holdings valued at $8,828,138,271 across 176 positions as of March 31, 2026. Top holdings include BJ's Wholesale Club Holdings ($344,811,813), White Mountains Insurance Group ($264,775,422), McGrath RentCorp ($238,297,104), Murphy USA ($195,505,422), and GXO Logistics ($183,608,161). This quarterly snapshot provides no period-over-period comparisons or performance metrics.

• ·Filing date: April 30, 2026
• ·Report period end: March 31, 2026
• ·Form type: 13F-HR (combination report)
• ·Business address: 462 South Fourth Street, Suite 2000, Louisville, KY 40202

30-04-2026

Glaukos Corp reported net sales of $150,571 thousand for the three months ended March 31, 2026, up 41.2% YoY from $106,664 thousand, with gross profit increasing 42.3% to $117,232 thousand. However, total operating expenses rose 33.1% YoY to $137,088 thousand, leading to an operating loss of $19,856 thousand (4.0% improvement YoY) but a net loss widening to $19,783 thousand from $18,146 thousand. Cash and equivalents grew to $104,249 thousand QoQ from $90,813 thousand, with net cash used in operations improving to $12,526 thousand from $18,521 thousand YoY.

• ·Short-term investments decreased to $172,436 thousand from $187,947 thousand QoQ.
• ·Inventory slightly declined to $62,384 thousand from $63,564 thousand QoQ.
• ·Total assets remained flat at $893,326 thousand vs $893,487 thousand QoQ.
• ·Stockholders' equity increased to $670,928 thousand from $656,155 thousand QoQ.
• ·Net cash provided by investing activities was $10,504 thousand vs used $36,948 thousand YoY.
• ·Proceeds from exercise of stock options: $19,330 thousand in Q1 2026.

30-04-2026

Vivos Therapeutics, Inc. filed an amended S-3 shelf registration statement to potentially issue securities, amid a business pivot from dentist training to a medical-provider focused model including the June 2025 acquisition of Sleep Center of Nevada (SCN) and Detroit-area MSO/DSO setups. The company highlights treatment of approximately 75,000 patients worldwide with its Vivos Method oral appliances, showing effectiveness in 80% of compliant OSA cases and AHI improvements in 88-91% of patients, but notes challenges like ending its Rebis Health alliance, ongoing operating losses, capital needs, and going concern risks tied to Nasdaq compliance. This evolution aims to scale via Sleep and Airway Medicine Centers (SAMC) but underscores reliance on future capital raises.

• ·Treatment course typically 9-12 months, with few reported relapses out of 75,000 patients.
• ·No longer offering Guided Growth and Development to unaffiliated dentists as of April 2026.
• ·SCN acquisition in June 2025 included sleep testing, diagnostics, and treatment centers.
• ·Rebis Health alliance ended due to unmet revenue expectations.

30-04-2026

Beam Wealth Advisors, Inc. filed its 13F-HR on April 30, 2026, reporting holdings as of March 31, 2026, across 108 securities with a total market value of $401,731,792. The portfolio is diversified with a heavy emphasis on ETFs, including top positions in iShares Core S&P 500 ETF ($73,425,678), VanEck Real Assets ETF ($28,767,586), and iShares MSCI Emerging China ETF ($22,840,464), alongside individual stocks such as Apple Inc. ($6,166,783) and NVIDIA Corporation ($8,609,457). All reported positions are held as sole discretionary shares with no indications of changes, shared voting, or performance rights.

• ·All 108 positions reported as SH SOLE with zero shared voting or performance rights.
• ·Holdings include cryptocurrency-related ETFs such as Grayscale Ethereum Staking ($354,254), Bitwise Ethereum ETF ($3,250,140), and Fidelity Ethereum Fund ($1,818,606).
• ·Former company name: BEAM Asset Management, LLC (changed 2020-02-13).
• ·Adviser CRD: 109867, SEC file: 801-60334.

30-04-2026

Total fees to the independent auditor declined 2.4% YoY to $9,672,480 in 2025 from $9,904,000 in 2024, driven by a 5.1% drop in audit fees to $8,514,570 despite a 21.2% rise in tax fees to $1,131,960. The 2020 incentive plan expired on May 21, 2025, leaving 76,646 QVCGA options and 492,473 RSUs/DSUs outstanding, with none of the 478,989 performance-based RSUs earned. Assumed HSN awards from the 2017 acquisition remain minimal, totaling 13,074 QVCGA options at a $613.70 weighted average exercise price.

• ·Audit-related fees in 2025: $22,450 (none in 2024).
• ·All other fees in 2025: $3,500 (none in 2024).
• ·Assumed HSN awards include 69 QVCGA and 104 QVCGP DSUs under 2008 plan, 110 QVCGA and 165 QVCGP DSUs under 2017 plan.
• ·May 2025 reverse stock split adjusted Ms. Dias’s awards.

30-04-2026

Bausch Health Companies Inc. reported Q1 2026 revenues of $2,524 up 11.7% YoY from $2,259, primarily driven by product sales growth of 12.3% to $2,500. However, a $1,426 goodwill impairment resulted in an operating loss of $950 versus prior year income of $276, and net loss attributable to the company widened to $1,423 from $58. Cash provided by operating activities edged up 9% to $230 while total assets declined to $24,498 from $26,366 at year-end.

• ·Goodwill decreased to $9,807 from $11,271 at Dec 31 2025 due to $1,426 impairment.
• ·Shareholders' deficit widened to $(2,059) from $(554) at Dec 31 2025.
• ·Long-term debt (current + non-current) totaled $20,764 at Mar 31 2026 versus $20,817 at Dec 31 2025.
• ·Small acquisition with $87 fair value of consideration transferred and $65 identifiable net assets.

30-04-2026

Prosperity Bancshares announced its merger with Stellar Bancorp on January 28, 2026, with all regulatory approvals received and closure expected on July 1, 2026, growing assets from $38B to $53-54B; Stellar reported strong Q1 adjusted net income of nearly $30M, exceeding annualized projections from the original $113M FY estimate. Management expressed optimism on NIM expansion to a combined 370 bps exit rate for 2026 and mid-40s efficiency ratio post-integration, with 35% cost savings targeted from Stellar. However, they cautioned on flat loan growth this year due to integration challenges and potential post-merger runoff across deals.

• ·Stellar core system conversion completed in February 2026.
• ·Integration timelines: American Bank September 2026, Texas Partners Bank November 2026, Stellar March 8, 2027.
• ·Expect continued share buybacks given capital levels post-Stellar (25-30% cash deal).
• ·Potential 100 bps repricing on Stellar securities portfolio post-merger.

30-04-2026

Mechanics Bancorp reported Q1 2026 net income of $44.1 million ($0.19 per diluted share), down significantly from $111.2 million ($0.48 per diluted share) in Q4 2025 due to the absence of a $55.1 million bargain purchase gain, higher $7.8 million provision for credit losses driven by geopolitical uncertainty, and $4.8 million in merger-related costs. Total assets declined to $21.4 billion, loans to $13.9 billion, and deposits to $18.2 billion QoQ amid repayments and deposit maturities; however, net interest margin expanded to 3.61% from 3.50%, cost of deposits fell to 1.28% from 1.43%, and credit quality improved with delinquent loans dropping to 0.56% of total loans. Capital ratios remained strong with CET1 at 13.91%, though slightly down from 14.09% QoQ.

• ·Provision for credit losses $7.8 million in Q1 2026 vs reversal of $3.2 million in Q4 2025, including $6.5 million related to geopolitical uncertainty.
• ·Noninterest-bearing deposits $6.5 billion (36% of total deposits) at March 31, 2026, down from $6.7 billion (35%) at Dec 31, 2025.
• ·Loans-to-deposits ratio 76% at March 31, 2026, up from 75% at Dec 31, 2025.
• ·Book value per share $12.61 at March 31, 2026, down from $12.93 at Dec 31, 2025; tangible book value per share $7.53, down from $7.81.

30-04-2026

Bed Bath & Beyond issued supplemental proxy materials responding to ISS's recommendation against the Say on Pay proposal, following a low 68.9% stockholder support in the 2025 advisory vote. The company engaged with stockholders representing 30% of outstanding shares and implemented changes for 2026 compensation, including adding revenue as a metric for bonuses and performance shares, holding target compensation flat for continuing executives (after 22%-48% grant decreases in 2025 vs. 2024), and extending vesting periods to four years. While these enhancements aim to better align pay with performance, the Compensation Committee noted limited specific feedback from stockholders on prior concerns.

• ·Independent Board members available for engagement upon request.
• ·Stockholders provided constructive feedback on incentive design and pay alignment, but no specific concerns on 2025 program.
• ·2026 performance shares vest 25% annually over four years based on goals set yearly.

30-04-2026

California Water Service Group reported Q1 2026 net income of $4.0 million ($0.07 per diluted share), a sharp decline from $13.3 million ($0.22 per diluted share) in Q1 2025, as results exclude benefits from the pending 2024 CA GRC decision; revenue rose 5.2% to $214.6 million from $204.0 million, but was offset by declining customer consumption (-$3.1 million) and higher operating expenses of $196.4 million (up from $181.6 million due to $8.3 million in water production costs and $4.0 million in depreciation). A revised PD in the 2024 CA GRC authorizes $90.5 million revenue increase (10.9%) for 2026, plus increases in 2027 and 2028; the company announced a $218 million acquisition of Nexus Water Group systems adding ~36,000 customer units and an 8% dividend increase to $1.34 annualized.

• ·Declining customer consumption decreased Q1 2026 revenue by $3.1 million.
• ·Short-term borrowings increased to $230 million from $130 million at Dec 31, 2025.
• ·Final 2024 CA GRC decision expected April 30, 2026 or shortly thereafter; rate increases retroactive to Jan 1, 2026.
• ·Quarterly dividend of $0.3350 per share payable May 22, 2026 to shareholders of record May 11, 2026.
• ·Group anticipates up to $627 million infrastructure investment in 2026 based on revised PD.

30-04-2026

Barinthus Biotherapeutics plc has filed a DEFM14A proxy statement for its Court Meeting and General Meeting on or around May 20, 2026, to seek shareholder approval for a Scheme of Arrangement dated April 22, 2026, as part of a merger transaction under the Merger Agreement (originally dated September 29, 2025, and amended February 22, 2026) involving Beacon Topco, Inc., Cdog Merger Sub, Inc., and Clywedog Therapeutics, Inc. The resolutions authorize directors to implement the Scheme, deliver the Court order, and amend the articles of association to bind new shares to the Scheme terms. No financial metrics or performance data are disclosed in the filing.

• ·Barinthus General Meeting scheduled at 2:15 p.m. London Time on May 20, 2026, at offices of Goodwin Procter (UK) LLP, Sancroft, 10-15 Newgate Street, London EC1A 7AZ
• ·Scheme of Arrangement dated April 22, 2026
• ·Original Merger Agreement dated September 29, 2025; Amendment dated February 22, 2026
• ·Court Meeting information available on www.barinthusbio.com

30-04-2026

FTAI Aviation Ltd. amended and extended its revolving credit facility, increasing total commitments from $400 million to $2.025 billion and extending the maturity to April 2031. The facility was oversubscribed—a record size for the company—and includes improved pricing terms to reduce borrowing costs and support growth opportunities. Banks led by JPMorgan Chase Bank as Administrative Agent participated, reflecting strong lender confidence.

• ·Facility led by JPMorgan Chase Bank as Administrative Agent and BNP Paribas, Citibank, MUFG Bank, PNC Bank, Royal Bank of Canada as Syndication Agents.
• ·Other participants include Barclays, Citizens Bank, Deutsche Bank, Goldman Sachs, Truist Bank as Co-Documentation Agents, plus Capital One, Standard Chartered, and U.S. Bank.
• ·Announcement made on April 29, 2026; SEC filing dated April 30, 2026.

30-04-2026

Viking Therapeutics reported no revenue for Q1 2026, with research and development expenses surging 263% YoY to $150,150 thousand due to increased clinical activities, resulting in a net loss of $158,325 thousand, more than tripling from $45,629 thousand in Q1 2025. Cash and cash equivalents declined 29% QoQ to $118,116 thousand from $165,810 thousand, driven by $114,000 thousand in operating cash use, though the company raised $12,077 thousand via stock issuances including an ATM offering. Total assets stood at $608,242 thousand with stockholders' equity at $501,917 thousand, reflecting accelerated cash burn but a maintained cash runway.

• ·Weighted-average shares for basic and diluted net loss per share: 115,568 thousand in Q1 2026 vs 112,069 thousand in Q1 2025.
• ·Basic and diluted net loss per share: $(1.37) in Q1 2026 vs $(0.41) in Q1 2025.
• ·Stock-based compensation expense: $10,337 thousand in Q1 2026 vs $11,348 thousand in Q1 2025.
• ·ATM offering net proceeds: $11,627 thousand in Q1 2026.

30-04-2026

Viewbix Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, changing its name to Quantum X Labs Inc., effective 12:01 a.m. Eastern Time on April 30, 2026. The amendment was approved by the Board of Directors and executed by CEO Amihay Hadad on April 29, 2026. The company was originally incorporated as Infergene Company on August 16, 1985.

• ·Originally incorporated under the name Infergene Company on August 16, 1985, in Delaware.

30-04-2026

Graham Holdings Company reported Q1 2026 revenue of $1,236.0 million, up 6% YoY from $1,165.9 million, with operating income rising 22% to $57.8 million driven by television broadcasting (+39%), manufacturing (+46%), while education declined 19% due to a $19.0 million impairment on Kaplan Languages Group (KLG) held for sale, healthcare fell 5%, and automotive dropped 18%. Adjusted operating cash flow increased 28% to $112.9 million, but net income was $29.1 million ($6.62 per share) impacted by $68.9 million net losses on marketable equity securities versus prior gains. The company announced an agreement to sell KLG (closing May 1, 2026) and Graham Healthcare Group acquired Covenant Home Health.

• ·Capital expenditures: $20.9 million in Q1 2026 vs. $14.1 million in Q1 2025.
• ·Net losses on marketable equity securities: $68.9 million in Q1 2026 vs. $43.8 million net gains in Q1 2025.
• ·Borrowings: $822.0 million at 5.8% average interest rate, including $149.1 million on revolving credit facility.
• ·Adjusted net income: $73.9 million ($16.79 per share) in Q1 2026 vs. $51.0 million ($11.64 per share) in Q1 2025.
• ·Board authorized up to 500,000 Class B shares repurchase on September 12, 2024.

30-04-2026

CNH Industrial N.V. reported Q1 2026 consolidated revenues of $3,826 million, flat YoY with Net Sales of Industrial Activities at $3,170 million also flat, while Agriculture net sales rose 1% to $2,596 million but Construction net sales declined 3% to $574 million. Net income fell 92% to $10 million and adjusted net income dropped 84% to $21 million, with Agriculture adjusted EBIT down 81% to $27 million (1.0% margin vs 5.4%) and Construction adjusted EBIT swinging to a $(28) million loss from $14 million profit. The company reaffirmed its full-year 2026 guidance, citing disciplined cost management amid low demand and trade challenges.

• ·North America ag industry volumes down 7% (tractors <140 HP), 27% (tractors >140 HP), 6% (combines); South America tractor demand down 8%, combines down 33%.
• ·Financial Services net income $74 million (down 18% YoY), receivables >30 days past due at 3.5% (up from 2.3%).
• ·2026 guidance: Agriculture net sales down 5% to flat, adj EBIT margin 4.5-5.5%; Construction net sales flat, adj EBIT margin 1.0-2.0%; Industrial FCF $150-350M; adj diluted EPS $0.35-0.45.

30-04-2026

Cat Financial reported Q1 2026 revenues of $947 million, up 10% from $860 million in Q1 2025, driven by higher average earning assets, with profit rising 11% to $144 million and retail new business volume increasing 8% to $3.19 billion. However, net write-offs increased to $29 million from $20 million, and total assets were essentially flat at $38,163 million compared to $38,313 million at year-end 2025. Past dues improved to 1.39% from 1.58%, while the allowance for credit losses remained stable at 0.86% of receivables.

• ·Higher general, operating and administrative expenses partially offset profit before tax growth by $22 million.
• ·Favorable impact from higher average earning assets contributed $40 million to profit before tax increase.

30-04-2026

Molson Coors reported Q1 2026 net sales up 2.0% to $2,351.1 million driven by 3.0% favorable price/sales mix, though financial volume declined 2.9% to 14.964 million hectoliters and brand volume fell 3.1%. U.S. GAAP income before income taxes rose 24.6% to $194.7 million with underlying diluted EPS up 24.0% to $0.62; however, Americas GAAP income before taxes dipped 0.9% while EMEA&APAC underlying losses widened 47.4% in constant currency to $(32.7) million amid lower volumes across segments.

• ·Announced acquisition of Monaco Cocktails to close portfolio gap.
• ·Expanded share-repurchase program.
• ·Reaffirmed full year guidance metrics.
• ·Net cash from operations improved $93.2 million to $2.5 million.
• ·Unfavorable Midwest Premium aluminum surcharge impact of approximately $30 million.
• ·Favorable unrealized mark-to-market commodity derivatives of $70.5 million.
• ·U.S. GAAP and underlying effective tax rate increased to 23% from 21%.

30-04-2026

Caterpillar Inc. reported first-quarter 2026 sales and revenues of $17.4 billion, up 22% YoY from $14.2 billion, driven by higher volume and pricing, with strong growth in Construction Industries (+38%) and Power & Energy (+22%). Profit per share rose to $5.47 (adjusted $5.54) from $4.20 ($4.25), while operating profit increased 20% to $3.085 billion; however, Resource Industries saw sales growth of only 4% and profit decline 39% to $378 million amid higher manufacturing costs including tariffs. The company deployed $5.7 billion in cash for share repurchases ($5.0 billion) and dividends ($0.7 billion), with enterprise operating cash flow at $1.9 billion.

• ·Adjusted operating profit margin declined to 18.0% from 18.3% YoY.
• ·Effective tax rate improved to 20.9% from 22.3% YoY, with a $68 million discrete tax benefit.
• ·Cat Financial past dues improved to 1.39% from 1.58%; write-offs increased to $29 million from $20 million.
• ·All Other Segment profit worsened to $(43) million from $(19) million.

30-04-2026

Laureate Education reported first quarter 2026 revenue of $272.6 million, up 15% YoY on a reported basis but only 1% on a constant currency basis due to $9 million of unfavorable intra-year academic calendar timing from later semester starts. New enrollments increased 9% and total enrollments rose 6%, however operating loss widened to $(27.5) million from $(13.2) million, net loss to $(21.6) million from $(19.6) million, and Adjusted EBITDA turned to $(2.3) million from $5.4 million, also impacted by higher depreciation and amortization. The company repurchased $105 million in shares and raised full-year 2026 Adjusted EPS guidance to $2.00-$2.08 per share, reflecting 16%-21% growth.

• ·Peru new enrollments +13% and total enrollments +8% during primary intake.
• ·Mexico new and total enrollments +4% during secondary intake.
• ·Remaining stock repurchase authorization: $76 million as of March 31, 2026.
• ·FY2026 guidance: Total enrollments 516,000-521,000 (4%-5% growth); Revenues $1,890-$1,905 million (11%-12% reported growth); Adjusted EBITDA $583-$593 million (12%-14% reported growth).
• ·Basic and diluted loss per share Q1 2026: $(0.15) vs $(0.13) in Q1 2025.

30-04-2026

Innventure, Inc. announced the resignation of director Daniel Hennessy effective April 29, 2026, resulting in temporary noncompliance with Nasdaq Listing Rule 5605(c)(2)(A) due to the Audit Committee having only two members, with a cure period expiring October 26, 2026. The Board appointed John Hewitt as an independent Class I director to fill the vacancy and nominated Catriona Fallon as an independent Class II director for election at the June 17, 2026 Annual Meeting. These changes aim to strengthen governance and oversight amid the company's scaling phase, following shareholder engagement including with Ascent Capital Partners.

• ·Nasdaq cure period for Audit Committee compliance expires October 26, 2026; company expects to appoint qualifying director by then.
• ·John Hewitt previously served as President of the Americas at Vertiv and holds board seat at Accelsius.
• ·Catriona Fallon expected to join Audit Committee if elected; currently chairs audit committees at Arlo Technologies and Palomar Holdings.
• ·Hennessy's resignation not due to any disagreement with company operations, policies, or practices.
• ·2026 Annual Meeting of Stockholders scheduled for June 17, 2026.

30-04-2026

Group 1 Automotive reported Q1 2026 total revenues of $5.4B, down 1.8% YoY from $5.5B, with net income from continuing operations at $129.9M, up slightly $2.1M from $127.7M, while adjusted net income fell to $104.0M from $134.7M. U.K. gross profits reached a record $230.6M (+6.3% YoY) and parts & service GP rose 5.0% to $400.0M, but new vehicle retail sales declined 4.4% to $2,562.4M and units sold dropped 6.6%. The company repurchased 205,190 shares for $72.4M and acquired three U.K. dealerships expected to add $135M in annual revenues, offsetting dispositions of dealerships generating $570M annually.

• ·Disposed of two Mercedes-Benz dealerships in California and one Volkswagen and one Skoda dealership in the U.K.
• ·Executed agreement with Geely to expand U.K. network through three new locations post-quarter.
• ·Diluted EPS from continuing operations $10.82 (includes $2.87 per share gain on asset dispositions); adjusted $8.66 vs. prior year $10.17.
• ·Remaining share repurchase authorization: $306.3M as of March 31, 2026.
• ·Owns 253 dealerships, 313 franchises, 32 collision centers offering 36 brands.

30-04-2026

InfuSystem Holdings, Inc. issued a press release on April 30, 2026, announcing the disclosure of its first quarter 2026 financial results on Thursday, May 7, 2026 before the market opens. The company will host a conference call for investors on the same day at 9:00 a.m. Eastern Time. No preliminary financial metrics or performance details were provided in the filing.

30-04-2026

Xerox Holdings Corporation reported Q1 2026 revenue of $1.85 billion, up 26.7% YoY or 23.6% in constant currency, primarily due to the Lexmark acquisition, though pro forma revenue declined 3.7% and Print segment pro forma revenue fell 3.5% while IT Solutions revenue dropped 4.9%. Adjusted operating income rose to $72 million with margin expansion of 240 basis points to 3.9%, but GAAP net loss widened to $(105) million from $(90) million and operating cash flow deteriorated to $(144) million from $(89) million. The company reaffirmed full-year guidance of revenue above $7.5 billion, adjusted operating income of $450-$500 million, and free cash flow of ~$250 million, while highlighting strategic progress like Lexmark synergies on track for at least $300 million and strengthened liquidity.

• ·Lexmark actual results included beginning July 1, 2025; pro forma includes estimated Lexmark Jan-Mar 2025.
• ·Print sales pipeline materially higher vs. prior year.
• ·Q1 IT Solutions billings growth of 21%.
• ·Free cash flow of $(165) million in Q1, with full-year guidance ~$250 million unchanged.
• ·Cash and cash equivalents increased to $585 million from $512 million at Dec 31, 2025.

30-04-2026

Hemab ApS reported consolidated financial results for the years ended December 31, 2024 and 2025 as part of its S-1/A IPO registration filing, showing total assets increasing from $96.3M to $194.8M driven by $156.4M net proceeds from Series C convertible preference shares issuance. However, net losses widened 31% YoY from $48.7M to $63.9M, primarily due to R&D expenses rising 44% to $59.6M, with cash used in operations increasing to $61.5M. Cash and equivalents grew modestly to $88.0M, while stockholders' deficit deepened to $176.6M.

• ·Liquidation preference on convertible preference shares increased to $350.1M as of Dec 31, 2025 from $186.4M as of Dec 31, 2024 due to Series C.
• ·Equity-based compensation expense was $1.9M in 2024 and $2.0M in 2025.
• ·Net cash provided by investing activities swung from +$61.9M in 2024 to -$81.5M in 2025 due to increased purchases of marketable securities.

30-04-2026

Quanta Services reported record first quarter 2026 consolidated revenues of $7.87 billion, a 26% increase YoY from $6.23 billion, with GAAP diluted EPS of $1.45 (up 51% from $0.96) and adjusted diluted EPS of $2.68 (up 51% from $1.78). Adjusted EBITDA reached a record $686.4 million, net income attributable to common stock was $220.6 million, cash flow from operations was $391.7 million, and total backlog hit a record $48.5 billion with remaining performance obligations of $26.2 billion. The company increased substantially all of its full-year 2026 financial expectations, including revenues to $34.7-35.2 billion and adjusted diluted EPS to $13.55-14.25.

• ·Completed eight acquisitions during full year 2025, with results included from respective acquisition dates
• ·FY 2026 adjusted diluted EPS guidance: $13.55-$14.25
• ·FY 2026 adjusted EBITDA guidance: $3.49B-$3.65B
• ·FY 2026 net cash provided by operating activities guidance: $2.35B-$2.85B
• ·FY 2026 free cash flow guidance: $1.55B-$2.05B
• ·Earnings webcast scheduled for April 30, 2026 at 9:00 a.m. Eastern Time

30-04-2026

Indivior reported Q1 2026 total net revenue of $317 million, up 19% YoY from $266 million, driven by SUBLOCADE net revenue of $232 million, up 32% YoY from $176 million, with adjusted EBITDA reaching a record $164 million, up 112% YoY from $78 million. The company raised full-year 2026 guidance, now expecting total net revenue of $1,215-1,285 million (prior $1,125-1,195 million) and adjusted EBITDA of $620-660 million (prior $535-575 million), while repurchasing $125 million in shares and completing a $500 million convertible notes offering. However, Indivior will not pursue Phase 3 development of INDV-6001 and is not advancing INDV-2000 internally after it missed its primary endpoint.

• ·GAAP net income Q1 2026: $89 million ($0.69 diluted EPS) vs $47 million ($0.38) in Q1 2025.
• ·Non-GAAP net income Q1 2026: $123 million ($0.96 diluted EPS) vs $56 million ($0.45) in Q1 2025.
• ·Cash and cash equivalents: $175 million as of March 31, 2026 (down from $195 million Dec 31, 2025).
• ·$275 million remaining under share repurchase program.
• ·Used majority of $500 million notes proceeds to repay $333 million term loan balance.
• ·Over 500,000 U.S. patients prescribed SUBLOCADE since launch.

30-04-2026

CCC Intelligent Solutions Holdings Inc. reported Q1 2026 revenue of $281.3 million, up 12% YoY from $251.6 million, with adjusted EBITDA increasing 21% to $120.2 million and margin expansion of approximately 300 basis points to 43%. GAAP operating income swung to $48.8 million from a $10.7 million loss, and adjusted operating income rose to $106.8 million. However, cash from operations slightly declined to $57.5 million from $58.5 million, free cash flow fell to $41.6 million from $43.6 million, and cash balances dropped to $36.9 million amid $400 million in share repurchases.

• ·Q2 2026 guidance: Revenue $283.0M to $285.0M; Adjusted EBITDA $111.0M to $113.0M.
• ·FY 2026 guidance: Revenue $1.155B to $1.163B; Adjusted EBITDA $484.0M to $490.0M.
• ·Added John Schweitzer to Board of Directors.
• ·Expanded relationship with top-five insurer (by 2024 direct premiums) via multi-year agreement for APD and AI solutions.
• ·Signed multi-year Casualty platform agreement with another top-five insurer; prior top-six insurer decision in Q4 2025.
• ·$100M remaining under $500M share repurchase authorization.
• ·Cash and cash equivalents decreased to $36.9M from $111.2M at Dec 31, 2025.

30-04-2026

Bridgewater Bancshares Inc reported robust YoY growth for Q1 2026, with net income rising 80.7% to $17,406 (thousands) from $9,633, net interest income up 21.3% to $36,647 (thousands), and EPS basic at $0.59 versus $0.31, fueled by higher loan interest income (+14.7%) and lower interest expense (-6.1%). However, the securities portfolio declined sharply 27% QoQ to $566,565 (thousands), total assets fell 1.3% QoQ to $5,335,396 (thousands), deposits dipped slightly 0.3% QoQ, and noninterest expenses increased 22.2% YoY to $22,170 (thousands). Provision for credit losses improved to $1,200 (thousands) from $1,500 (thousands) YoY.

• ·Net gain on sales of available for sale securities: $7,251 (thousands) in Q1 2026 vs $1 (thousands) in Q1 2025
• ·FHLB Advances: $336,000 (thousands) at March 31, 2026 vs $399,500 (thousands) at Dec 31, 2025
• ·Allowance for Credit Losses: $57,277 (thousands) at March 31, 2026 vs $56,443 (thousands) at Dec 31, 2025
• ·Cash and Cash Equivalents increased $98,643 (thousands) in Q1 2026
• ·Proceeds from sales of securities: $208,501 (thousands) in Q1 2026

30-04-2026

Carrier Global Corporation reported Q1 2026 net sales of $5,341 million, up 2% YoY from $5,218 million, though organic sales declined 1%; Commercial HVAC orders rose 35% with data center orders up over 500%, while total company orders increased 11%. GAAP operating profit fell 59% to $259 million and adjusted operating profit dropped 30% to $594 million, with GAAP EPS down 40% to $0.28 and adjusted EPS down 12% to $0.57 amid declines in CSA Residential and China RLC. The company generated $79 million in net cash from operating activities but negative free cash flow of ($15) million, reaffirming full-year 2026 guidance of ~$22 billion in sales and adjusted EPS of ~$2.80.

• ·CSA Residential sales down ~12% YoY; Light commercial up 9%, Commercial up 1%.
• ·CSE organic sales flat; RLC up low-single digits, Commercial down mid-single digits.
• ·CSAME organic sales down 1%, driven by China RLC headwinds, offset by Commercial growth in India and Australia.
• ·CST organic sales up 5%; Container up 38%, Global Truck and Trailer down high-single digits.
• ·Full-year 2026 guidance: Organic sales flat to low-single digits; FX 1%, Net Acq/Divest (1%), ~$250M revenue headwind from Riello exit; Adjusted Op Profit ~$3.4B; Adjusted EPS ~$2.80; FCF ~$2B.
• ·Riello divestiture expected to close by end of Q2 2026.

30-04-2026

Warner Bros. Discovery, Inc. (WBD) filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders on April 30, 2026, seeking election of 13 director nominees (92% or 12 of 13 independent, average independent tenure 5 years), ratification of PricewaterhouseCoopers LLP as independent auditors for fiscal 2026, and advisory approval of 2025 named executive officer compensation, while recommending against a stockholder proposal from the National Center for Public Policy Research. The Board emphasizes nominees' diverse skills and experience for oversight of strategy execution. No specific financial performance metrics or period-over-period changes are detailed in the filing.

• ·2026 Annual Meeting scheduled as virtual event beginning 9:45 a.m. ET on June 9, 2026 at www.virtualshareholdermeeting.com/WBD2026.
• ·Audit firm appointment for fiscal year ending December 31, 2026.
• ·Advisory vote on 2025 executive compensation.

30-04-2026

Merck & Co., Inc. reported first-quarter 2026 worldwide sales of $16.3 billion, up 5% YoY (3% ex-FX), driven by strong growth in KEYTRUDA ($8.0 billion, +12%), WINREVAIR ($525 million, +88%), and Animal Health ($1.8 billion, +13%), but offset by declines including GARDASIL (-19%), JANUVIA/JANUMET (-28%), ROTATEQ (-10%), VAXNEUVANCE (-12%), and LAGEVRIO (-73%). GAAP and non-GAAP loss per share were $1.72 and $1.28, respectively, compared to profits of $2.01 and $2.22 in Q1 2025, primarily due to a $3.62 per share ($9.0 billion) charge for the Cidara Therapeutics acquisition. The company narrowed and raised its full-year 2026 guidance to worldwide sales of $65.8-$67.0 billion and non-GAAP EPS of $5.04-$5.16, excluding the pending Terns Pharmaceuticals acquisition expected to close in May with a $5.8 billion charge.

• ·U.S. FDA approval for IDVYNSO, a once-daily oral treatment for certain adults with virologically suppressed HIV-1.
• ·Presented new data from cardio-pulmonary pipeline at ACC.26, including positive Phase 3 CORALreef AddOn Trial results.
• ·Agreement to acquire Terns Pharmaceuticals, Inc. to expand hematology pipeline with TERN-701 for chronic myeloid leukemia; expected to close in May 2026.
• ·OHTUVAYRE sales of $131 million from October 2025 Verona Pharma acquisition.
• ·Koselugo alliance revenue $161 million in Q1 2026 vs. $44 million in Q1 2025 due to collaboration amendment with AstraZeneca.

30-04-2026

Labcorp reported Q1 2026 revenue of $3.54 billion, up 5.8% YoY from $3.35 billion, with Adjusted EPS rising 10.6% to $4.25; Diagnostics revenue grew 5.0% to $2.76 billion while Biopharma Laboratory Services increased 8.2% to $780.6 million. The company raised full-year 2026 guidance, with revenue growth now at 5.0%-6.1% and Adjusted EPS midpoint to $18.03, up $0.13. However, Diagnostics organic price/mix grew only 1.1% due to adverse weather, Biopharma organic growth was 3.7% with acquisitions net -1.0%, and operating cash flow improved from a low $18.5 million base.

• ·TTM Book to Bill ratio of 1.04x as of March 31, 2026.
• ·Next Twelve Months Forecast Backlog Conversion of $2.69B.
• ·Quarterly dividend of $0.72 per share announced April 9, 2026, payable June 11, 2026.
• ·Backlog increased 5.6% YoY.

30-04-2026

Baxter International Inc. reported first-quarter 2026 sales from continuing operations of $2.7 billion, increasing 3% on a reported basis but declining 1% organically, with U.S. sales down 4% to $1.44 billion while international sales rose 12% reported (3% organic) to $1.27 billion. Segment results were mixed: Medical Products & Therapies sales of $1.3 billion declined 2% organically, Healthcare Systems & Technologies at $705 million were flat reported (down 2% organic), and Pharmaceuticals grew 7% reported (1% organic) to $621 million; adjusted diluted EPS from continuing operations was $0.36, down 35% YoY. The company reiterated its full-year 2026 outlook for flat to 1% reported sales growth, approximately flat organic growth, and adjusted EPS of $1.85 to $2.05.

• ·GAAP diluted EPS (loss) from continuing operations of ($0.03); net income (loss) from continuing operations ($17) million.
• ·Full-year 2026 outlook: reported sales growth flat to 1%, organic sales growth approximately flat, adjusted EPS $1.85 to $2.05.
• ·Kidney Care business divested in January 2025, reported as discontinued operations.
• ·Upcoming investor events: BofA Securities 2026 Health Care Conference (May 13, 2026), Goldman Sachs 47th Annual Global Healthcare Conference (June 9, 2026).

30-04-2026

Verano Holdings Corp. reported Q1 2026 net revenue of $208 million, up 1% QoQ from $207 million but down 1% YoY from $210 million, with growth in retail offset by wholesale competition and promotions. Gross profit declined to $99 million (48% margin) from $106 million (51%) QoQ and was slightly below $100 million YoY, while Adjusted EBITDA improved to $49 million (24% margin) versus $56 million QoQ and $54 million YoY; however, net loss widened to $(18) million from $(12) million YoY due to debt repayment costs. The company secured a $195 million term loan and $100 million revolving facility, authorized a $20 million share repurchase, and opened new Florida dispensaries amid cannabis rescheduling momentum.

• ·Net cash provided by operating activities: $19 million in Q1 2026, up from $2 million in Q1 2025.
• ·2026 guidance reiterates capital expenditures of $30 million to $50 million.
• ·Conference call scheduled for April 30, 2026 at 8:30 a.m. ET.
• ·Cannabis rescheduling announcement on April 23, 2026.